Novo Nordisk
NVO
₹6,179
Share price
-1.92%
Change (1 day)
-42.60%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Novo Nordisk (NVO) - Total debt
Total debt on the balance sheet as of December 2024 : ₹1.227 Trillion
According to Novo Nordisk's latest financial reports the company's total debt is ₹1.227 Trillion. A company’s total debt is the sum of all current and non-current debts.
Novo Nordisk - Total debt on balance sheet (from 1996 to 2024)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | ₹1.230 T | 269.51% |
| 2023-12-31 | ₹332.96 B | 8.37% |
| 2022-12-31 | ₹307.25 B | 1.76% |
| 2021-12-31 | ₹301.94 B | 141.18% |
| 2020-12-31 | ₹125.19 B | 161.19% |
| 2019-12-31 | ₹47.93 B | 768.78% |
| 2018-12-31 | ₹5.51 B | -68.36% |
| 2017-12-31 | ₹17.43 B | 691.39% |
| 2016-12-31 | ₹2.20 B | -78.91% |
| 2015-12-31 | ₹10.44 B | 40.21% |
| 2014-12-31 | ₹7.45 B | 203.07% |
| 2013-12-31 | ₹2.45 B | -49.34% |
| 2012-12-31 | ₹4.85 B | -38.25% |
| 2011-12-31 | ₹7.86 B | -55.8% |
| 2010-12-31 | ₹17.78 B | 43.36% |
| 2009-12-31 | ₹12.40 B | -40.79% |
| 2008-12-31 | ₹20.95 B | 99.81% |
| 2007-12-31 | ₹10.48 B | -11.82% |
| 2006-12-31 | ₹11.89 B | -37.99% |
| 2005-12-31 | ₹19.17 B | 42.54% |
| 2004-12-31 | ₹13.45 B | 0.86% |
| 2003-12-31 | ₹13.34 B | 38.16% |
| 2002-12-31 | ₹9.65 B | -18.3% |
| 2001-12-31 | ₹11.81 B | -1.14% |
| 2000-12-31 | ₹11.95 B | -5.44% |
| 1999-12-31 | ₹12.64 B | -25.72% |
| 1998-12-31 | ₹17.02 B | -3.85% |
| 1997-12-31 | ₹17.70 B | 47.65% |
| 1996-12-31 | ₹11.98 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 | ₹5.448 T | 343.79% | 🇺🇸 USA |
 | ₹2.879 T | 134.58% | 🇺🇸 USA |
 | ₹4.382 T | 256.99% | 🇺🇸 USA |
 | ₹1.595 T | 29.92% | 🇫🇷 France |